August 29, 2018
FDA proposes not including three bulk drug substances that outsourcing facilities may use in compounding
Editor's Note
The Food and Drug Administration (FDA) on August 28 issued a notice proposing not to include three bulk FDA-approved drug substancesābumetanide, nicardipine hydrochloride, and vasopressināon the list that outsourcing facilities may use in compounding drug products.
The FDA is seeking public comment before finalizing their decision. Comments must be received by October 29, 2018.
Free Daily News
- Hospital safety grades show progress in reducing medical errors, infections
- Analysis: Overuse of back surgeries costs Medicare $2 billion, risks patient safety
- AI-powered surgical robot learns by watching
- AHA's Congressional "wish list" calls for financial relief, patient access, workforce protections
- Out-of-hospital cardiac arrest survival rates lag pre-pandemic levels, racial disparities persist
- Honoring the OR Manager Award winners this Perioperative Nurses Week
- Study: Demand for anesthesiologists rises sharply, driven by job market, regional variations
- Joint Commission Sentinel Event Alert details environmental disaster preparation
- ACS recognizes 77 hospitals for excellence in surgical outcomes
- Color-changing gel could enhance cataract surgery safety, efficiency
© Access Intelligence, LLC. All rights reserved. |
Privacy Policy |
Cookie Settings |
Diversity, Equity, Inclusion & Belonging |
Accessibility Statement